Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study published in Circulation Research shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.

Illustration of artherosclerosis © SHUTTERSTOCK

Atherosclerosis is a disease in which fatty substances build-up within an artery, creating a plaque. Inflammatory processes, in particular monocyte and macrophage supply and recruitment, are key to the development of atherosclerosis, which over time can harden the arteries, restricting blood flow and oxygen supply to vital organs and increasing the risk of serious complications of cardiovascular disease such as strokes and heart attacks. 

During the study Claudia Monaco, lead author, found that CD200 deficiency led to increased monopoiesis and an accumulation of monocytes and macrophages during atherogenesis, leading to worse atherosclerosis. However, by administrating a CD200-Fusion protein to activate the pathway, the team found that neointima formation, was reduced. 

“Both systemic and local components of the immune system are important in atherogenesis, and CD200 can regulate both systemic and local inflammatory factors by acting within the artery wall but also on monopoiesis in the bone marrow,” said Claudia.  

CD200 controls macrophage activation by interacting with the inhibitory receptor CD200R. The CD200 - CD200R pathway was shown to restrain activation of CD200R+ lesional macrophages, their production of CCR2 ligands, and monocyte recruitment in vitro and in vivo in an air pouch model. 

Bone marrow chimera experiments performed by the team revealed that the CD200 – CD200R pathway enables two complementary and tissue dependent strategies to limit atherogenesisCD200 expression by bone-marrow derived cells limits systemic monocytosis, while CD200 expression by non-haematopoietic cells, for example endothelial cells, prevents local plaque growth, said Claudia. 

This is the first study to reveal a role for the CD200/CD200R pathway in atherosclerosis and it makes it a possible target for finding a potential therapeutic pathway to treat cardiovascular disease. This research was supported by the British Heart Foundation, The European Commission, the Kennedy trustees and the Novo Nordisk Foundation. 

The research is explained in Nature Reviews Cardiology. 

Similar stories

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.